文献速递淋巴瘤

增强STING激动剂对淋巴瘤免疫治疗的临床前模型研究

Enhancing immunotherapy of STING agonist for lymphoma in preclinical models.
PubMed 文献 · Blood Adv · 2018-01-01

在淋巴瘤临床前模型中,瘤内注射STING激动剂(STINGa)引起的局部肿瘤消退完全依赖宿主的STING表达,属免疫介导;远处未治疗肿瘤仅受微弱影响。联合抗GITR抗体可诱导引流淋巴结淋巴细胞扩增及远处肿瘤T细胞浸润增加,其中更多CD8 T细胞表达PD-1,进一步阻断PD-1使50%小鼠远处肿瘤获得治愈。

要点

  • 局部肿瘤消退完全依赖宿主STING表达,属免疫介导而非直接治疗作用。
  • 单点注射STINGa对远处未治疗肿瘤影响微弱。
  • 联合抗GITR与抗PD-1抗体可使50%小鼠远处肿瘤治愈。

核心结论

  • 临床前数据支持将瘤内注射STINGa后联合激动性抗GITR抗体与抗PD-1抗体作为人淋巴瘤免疫治疗的依据。

研究设计与样本

  • 采用野生型或STING敲除宿主、携带野生型或STING敲除肿瘤细胞的临床前模型。
  • 使用目前正在临床试验中测试的STINGa,筛选可协同STING通路诱导全身抗肿瘤免疫的免疫调节剂。

主要发现

  • 局部肿瘤消退完全依赖宿主的STING表达,因此是免疫介导的。
  • 向单个肿瘤部位注射STINGa后,远处未治疗肿瘤仅受微弱影响。
  • 调节APC和T细胞均可增强STINGa对远处淋巴瘤肿瘤的控制。
  • 加用抗GITR抗体诱导治疗部位引流淋巴结中淋巴细胞扩增,随后远处肿瘤T细胞浸润增加。
  • 远处部位更多CD8 T细胞表达PD-1,阻断PD-1进一步加强对远处肿瘤的控制,使50%的小鼠获得治愈。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Direct activation of tumor infiltrating antigen-presenting cells (APCs) by intratumoral injection of STING agonists (STINGa) leads to regression of the treated lymphoma tumor. Because STING activation induces apoptosis in lymphoma cells in vitro, we distinguished between the direct therapeutic vs the indirect immunotherapeutic properties of STINGa in vivo. Employing wild-type or STING knockout hosts bearing either wild-type or STING knockout tumor cells, we demonstrated that local tumor regression is totally dependent on STING expression by the host and is therefore immune mediated. However, distant untreated tumors are weakly affected after injection of STINGa to a single tumor site. Therefore, using the STINGa currently being tested in clinical trials, we screened for immunomodulatory agents that could synergize with the STING pathway to induce a systemic antitumor immune response and regression of distant tumors. We combined the STINGa with agents that improve APC or T-cell function. We found that modulation of both APCs and T cells can enhance control of distant lymphoma tumors by STINGa. In particular, adding an anti-GITR antibody induced lymphocyte expansion in the lymph node draining the treated site followed by increased T-cell infiltration in the distant tumor. Furthermore, more of these CD8 T cells at the distant site expressed PD-1. Therefore, blockade of PD-1 further enhanced tumor control at the distant site, leading to cure in 50% of the mice. These preclinical data provide the rationale for testing local injection of STINGa followed by agonistic anti-GITR and anti-PD-1 antibodies as immunotherapy for human lymphoma.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sallets A, Robinson S, Kardosh A, et al. Enhancing immunotherapy of STING agonist for lymphoma in preclinical models. Blood Adv. 2018. PMID: 30194137. doi:10.1182/bloodadvances.2018020040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。